Show simple item record

2021-11-25Zeitschriftenartikel
Analysis of BNT162b2- and CVnCoV-elicited sera and of convalescent sera toward SARS-CoV-2 viruses
dc.contributor.authorHein, Sascha
dc.contributor.authorHerrlein, Marie-Luise
dc.contributor.authorMhedhbi, Ines
dc.contributor.authorBender, Daniela
dc.contributor.authorHaberger, Vanessa
dc.contributor.authorBenz, Nuka
dc.contributor.authorEisert, Jonathan
dc.contributor.authorStingl, Julia
dc.contributor.authorDreher, Michael
dc.contributor.authorOberle, Doris
dc.contributor.authorSchulze, Jessica
dc.contributor.authorMache, Christin
dc.contributor.authorBudt, Matthias
dc.contributor.authorHildt, Christoph
dc.contributor.authorWolff, Thorsten
dc.contributor.authorHildt, Eberhard
dc.date.accessioned2024-08-13T16:09:59Z
dc.date.available2024-08-13T16:09:59Z
dc.date.issued2021-11-25none
dc.identifier.other10.1111/all.15189
dc.identifier.urihttp://edoc.rki.de/176904/11909
dc.description.abstractBackground The mRNA vaccine BNT162b2 (Comirnaty, BioNTech/Pfizer) and the vaccine candidate CVnCoV (Curevac) each encode a stabilized spike protein of SARS-CoV2 as antigen but differ with respect to the nature of the mRNA (modified versus unmodified nucleotides) and the mRNA amount (30 μg versus 12 μg RNA). This study characterizes antisera elicited by these two vaccines in comparison to convalescent sera. Methods Sera from BNT162b2 vaccinated healthcare workers, and sera from participants of a phase I trial vaccinated with 2, 4, 6, 8, or 12 μg CVnCoV and convalescent sera from hospitalized patients were analyzed by ELISA, neutralization tests, surface plasmon resonance (SPR), and peptide arrays. Results BNT162b2-elicited sera and convalescent sera have a higher titer of spike-RBD-specific antibodies and neutralizing antibodies as compared to the CVnCoV-elicited sera. For all analyzed sera a reduction in binding and neutralizing antibodies was found for the lineage B.1.351 variant of concern. SPR analyses revealed that the CVnCoV-elicited sera have a lower fraction of slow-dissociating antibodies. Accordingly, the CVnCoV sera almost fail to compete with the spike-ACE2 interaction. The significance of common VOC mutations K417N, E484K, or N501Y focused on linear epitopes was analyzed using a peptide array approach. The peptide arrays showed a strong difference between convalescent sera and vaccine-elicited sera. Specifically, the linear epitope at position N501 was affected by the mutation and elucidates the escape of viral variants to antibodies against this linear epitope. Conclusion These data reveal differences in titer, neutralizing capacity, and affinity of the antibodies between BNT162b2- and CVnCoV-elicited sera, which could contribute to the apparent differences in vaccine efficacy.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY-NC-ND 3.0 DE) Namensnennung - Nicht-kommerziell - Keine Bearbeitung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/de/
dc.subjectantiseraeng
dc.subjectmRNAeng
dc.subjectSARS-CoV-2eng
dc.subjectvaccineeng
dc.subjectvariants of concerneng
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titleAnalysis of BNT162b2- and CVnCoV-elicited sera and of convalescent sera toward SARS-CoV-2 virusesnone
dc.typearticle
dc.identifier.urnurn:nbn:de:0257-176904/11909-0
dc.type.versionpublishedVersionnone
local.edoc.container-titleAllergynone
local.edoc.container-issn1398-9995none
local.edoc.pages10none
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://onlinelibrary.wiley.com/journal/13989995none
local.edoc.container-publisher-nameJohn Wiley & Sons, Incnone
local.edoc.container-reportyear2021none
dc.description.versionPeer Reviewednone

Show simple item record